Impact of pro-resolution mediators in the control of thromboinflammatory responses
BHF-funded researchers in Reading are looking to understand what exactly happens during blood clotting, so that new medicines can stop its harmful effects while preserving the life-saving ones. Platelets are small circulating blood cells that play important roles in blood clotting to prevent excessive bleeding, for example, after we cut ourselves. However, their unwarranted activation leads to the formation of clots in blood vessels. This can result in life-threatening conditions such as heart attacks and strokes. Current antiplatelet drugs help to save lives, but they also have side effects. The development of new treatments to prevent dangerous blood clotting is a pressing priority. Finding a medicine that prevents unwanted blood clots, while allowing the body to heal injuries, is a difficult balancing act. These researchers are deciphering the precise molecular ways in which platelets work, to spotlight potential ways for this balance to be struck. In this study, they aim to uncover how key proteins on the surface of platelets, called FPR2/ALX, receive signals that change how platelets behave. Insights from this project will provide clues that could lead to new antiplatelet agents that safely fight the risk of harmful blood clots.
Project details
| Grant amount | £221,767 |
|---|---|
| Grant type | Project Grants |
| Application type | Project Grant |
| Start Date | 01 December 2019 |
| Duration | 3 years |
| Reference | PG/19/62/34593 |
| Status | In Progress |
